Additionally, there are problems in sourcing patients for clinical trials and patient non-compliance, unsustainable spending patterns, product safety, globalization and a shift from more provider-centric business model towards a patient-centric business model. There is also a problem with the increased expense of creating innovative life-saving drugs and the reduction in compensation, pricing burdens and easy access to some drugs such as acid reducers. The negative view of the pharmaceutical industry would be an economic environment that reduces investment in real innovations and scientific boldness, lack of teamwork, data and resource sharing between public and private organizations. Another negative view would be the useless methods that are used to find and create new and recent products (Grom,